Transcatheter aortic valve implantation: changing patient populations and novel indications

摘要

TAVI is clearly a disruptive technology that is in the midst of causing a significant paradigm shift in the management of patients with AS. Although it has been only a decade since the first clinical case was performed, worldwide experience now exists in excess of 50 000 patients and we are now experiencing the maturing of that disruptive technology.